Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Earnings release covers three and nine months ended September 30, 2026.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Earnings release covers three and nine months ended September 30, 2026
- Exhibit 99.1 contains Ligand’s financial results and provides the substantive investor detail
- Disclosure furnished under Regulation FD, not deemed filed under Exchange Act Section 18 liability provisions
Item EX-99.1 · Exhibit EX-99.1
- Q3 royalty revenue $70.3M, up 51% YoY, confirming XOMA assets and core products are accelerating recurring revenue
- Total revenue $78.7M, down 32% YoY, distorted by $53.1M of prior-year Pelthos-related income
- GAAP net loss $28.5M, or $1.43 per share, driven by $39.5M of pre-tax investment losses
- Adjusted EPS $2.67, down 14% YoY, despite royalty growth due to higher operating expenses and lost Pelthos income
- 2026 adjusted EPS guidance raised to $9.50 to $9.75, while revenue guidance remains $270M to $310M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.